Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stahist T is an over-the-counter (OTC) antihistamine containing triprolidine hydrochloride, a first-generation histamine H1 receptor antagonist. Developed and marketed by Magna Pharmaceuticals, it is indicated for the temporary relief of symptoms associated with allergic rhinitis (hay fever), the common cold, and other upper respiratory allergies, such as runny nose, sneezing, and itchy/watery eyes. As a small molecule drug, triprolidine works by competitively blocking H1 receptors, thereby inhibiting the effects of histamine on capillaries, bronchial muscle, and gastrointestinal smooth muscle. It is often recommended for use at bedtime due to its potential for drowsiness and its ability to dry secretions. The tablets are scored to allow for customized half-tablet dosing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Stahist T.